home / stock / rare / rare news

RARE News and Press, Ultragenyx Pharmaceutical Inc.

Stock Information
Company Name: Ultragenyx Pharmaceutical Inc.
Stock Symbol: RARE
Market: NASDAQ
Website: ultragenyx.com
Menu
RARE RARE Quote RARE Short RARE News RARE Articles RARE Message Board
Get RARE Alerts

News, Short Squeeze, Breakout and More Instantly...
RARE - Ultragenyx Pharmaceutical Inc. (RARE) Presents at Leerink Global Healthcare Conference 2026 Transcript

2026-03-11 12:32:31 ET Ultragenyx Pharmaceutical Inc. (RARE) Leerink Global Healthcare Conference 2026 March 11, 2026 10:00 AM EDT... Read the full article on Seeking Alpha For further details see: Ultragenyx Pharmaceutical Inc. (RARE) Presents at Leerink Global Healthcare C...
RARE - LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION

LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION PR Newswire Important Information Rega...

RARE - Ultragenyx Pharmaceutical Inc. (RARE) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

2026-03-10 15:10:16 ET Ultragenyx Pharmaceutical Inc. (RARE) Barclays 28th Annual Global Healthcare Conference March 10, 2026 12:00 PM EDT... Read the full article on Seeking Alpha For further details see: Ultragenyx Pharmaceutical Inc. (RARE) Presents at Barclays 28th Annua...

RARE - LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSURE

LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSURE LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSURE PR Newswire Alert: Claims Focus on Alleged Misrepresentations About Setrus...
RARE - Ultragenyx Pharmaceutical Inc. (RARE) Presents at TD Cowen 46th Annual Health Care Conference Transcript

2026-03-02 16:47:51 ET Ultragenyx Pharmaceutical Inc. (RARE) TD Cowen 46th Annual Health Care Conference March 2, 2026 1:50 PM EST... Read the full article on Seeking Alpha For further details see: Ultragenyx Pharmaceutical Inc. (RARE) Presents at TD Cowen 46th Annual Health...

RARE - LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION

LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION PR Newswire Time-Sensitive: Allega...

RARE - Ultragenyx to Participate at Investor Conferences in March

NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in three upcoming invest...
RARE - Rare disease pharmas could benefit from FDA guidance to accelerate development

2026-02-23 14:34:32 ET More on CRISPR Therapeutics, Intellia Therapeutics Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript Crispr: Emphasis Shifts...

RARE - Ultragenyx granted FDA priority review for rare metabolic disorder gene therapy

2026-02-23 10:59:56 ET More on Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline Ultragenyx Pharmaceutical Inc. (RARE) Presents at ...

RARE - Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

PDUFA action date set for August 23, 2026 If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the U.S. Food and Drug Administration (FDA or t...
Next 10